$GOSS

Chardan initiated coverage on Gossamer Bio (NASDAQ:GOSS) with a Buy rating and $160 price target, citing potential FDA approval of seralutinib for PAH therapy. The stock is near its 52-week low at $9.28. The company has a market cap of $56.76M and faces an NDA decision in Q4 2026. Chardan estimates $1.3B in 2035 revenue if approved. Gossamer recently submitted an NDA for seralutinib, supported by clinical trial data. Leerink and H.C. Wainwright also issued positive ratings.

Gossamer Bio, Inc. (GOSS) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On September 25, 2026, Gossamer Bio, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company has regained compliance with the minimum bid price requirement for con

Gossamer Bio submitted an NDA to the FDA for seralutinib to treat pulmonary arterial hypertension. The submission is based on phase 3 PROSERA and phase 2 TORREY study data. The phase 3 trial did not meet its primary endpoint. This is Gossamer's first NDA submission.

Gossamer Bio (GOSS) shares rose 3.7% after-hours after submitting a New Drug Application for seralutinib, a treatment for pulmonary arterial hypertension, to the FDA. The submission is backed by Phase 3 and Phase 2 study data. The FDA will decide whether to accept the application for review later this year.

Gossamer Bio, Inc. (GOSS) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On September 23, 2026, Gossamer Bio, Inc. (the “Company”) announced that it submitted a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) in September 2026 for seralutinib for the treatment of pulmonary arterial hypertension (“P

Gossamer Bio, Inc. (GOSS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Gossamer Bio Appoints Greg Ciongoli to Board of Directors SAN DIEGO — (BUSINESS WIRE) — September 16, 2026 — Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatmen

Gossamer Bio (GOSS) fell 6.14% to $10.69 after completing a 1-for-80 reverse stock split. The company's shares are now trading on a split-adjusted basis. The stock's 52-week range is $9.10 to $309.60.

Gossamer Bio, Inc. (GOSS) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split September 11, 2026 SAN DIEGO—(BUSINESS WIRE)— September 11, 2026 — Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the developm

Gossamer Bio (GOSS) announced a 1-for-80 reverse stock split and reduced authorized shares to 50M to comply with Nasdaq's minimum bid price requirement. The split is effective September 10, 2026, with trading adjustments on September 11, 2026. Convertible notes, warrants, and equity awards will be proportionately adjusted.

Gossamer Bio (GOSS) filed a Form D notice with the SEC, raising $125M through private securities offerings. The biotech firm, based in San Diego, did not disclose revenue. The offering includes options, warrants, and other rights to acquire securities. Leerink Partners LLC is involved as a broker-dealer.